3so3 Citations

A reverse binding motif that contributes to specific protease inhibition by antibodies.

J Mol Biol 415 699-715 (2012)
Cited: 36 times
EuropePMC logo PMID: 22154938

Abstract

The type II transmembrane serine protease family consists of 18 closely related serine proteases that are implicated in multiple functions. To identify selective, inhibitory antibodies against one particular type II transmembrane serine protease, matriptase [MT-SP1 (membrane-type serine protease 1)], a phage display library was created with a natural repertoire of Fabs [fragment antigen binding (Fab)] from human naïve B cells. Fab A11 was identified with a 720 pM inhibition constant and high specificity for matriptase over other trypsin-fold serine proteases. A Trichoderma reesei system expressed A11 with a yield of ∼200 mg/L. The crystal structure of A11 in complex with matriptase has been determined and compared to the crystal structure of another antibody inhibitor (S4) in complex with matriptase. Previously discovered from a synthetic single-chain variable fragment library, S4 is also a highly selective and potent matriptase inhibitor. The crystal structures of the A11/matriptase and S4/matriptase complexes were solved to 2.1 Å and 1.5 Å, respectively. Although these antibodies, discovered from separate libraries, interact differently with the protease surface loops for their specificity, the structures reveal a similar novel mechanism of protease inhibition. Through the insertion of the H3 variable loop in a reverse orientation at the substrate-binding pocket, these antibodies bury a large surface area for potent inhibition and avoid proteolytic inactivation. This discovery highlights the critical role that the antibody scaffold plays in positioning loops to bind and inhibit protease function in a highly selective manner. Additionally, Fab A11 is a fully human antibody that specifically inhibits matriptase over other closely related proteases, suggesting that this approach could be useful for clinical applications.

Articles - 3so3 mentioned but not cited (4)

  1. A reverse binding motif that contributes to specific protease inhibition by antibodies. Schneider EL, Lee MS, Baharuddin A, Goetz DH, Farady CJ, Ward M, Wang CI, Craik CS. J Mol Biol 415 699-715 (2012)
  2. Molecular Dynamics Simulations of Specific Anion Adsorption on Sulfobetaine (SB3-14) Micelles. Santos DP, Longo RL. J Phys Chem B 120 2771-2780 (2016)
  3. Dimeric W3SO3 cluster complexes: synthesis, characterization, and potential applications as X-ray contrast agents. Yu SB, Droege M, Downey S, Segal B, Newcomb W, Sanderson T, Crofts S, Suravajjala S, Bacon E, Earley W, Delecki D, Watson AD. Inorg Chem 40 1576-1581 (2001)
  4. Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity. Sevillano N, Bohn MF, Zimanyi M, Chen Y, Petzold C, Gupta S, Ralston CY, Craik CS. Biochim Biophys Acta Proteins Proteom 1869 140562 (2021)


Reviews citing this publication (4)

Articles citing this publication (28)

  1. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. Kenniston JA, Faucette RR, Martik D, Comeau SR, Lindberg AP, Kopacz KJ, Conley GP, Chen J, Viswanathan M, Kastrapeli N, Cosic J, Mason S, DiLeo M, Abendroth J, Kuzmic P, Ladner RC, Edwards TE, TenHoor C, Adelman BA, Nixon AE, Sexton DJ. J Biol Chem 289 23596-23608 (2014)
  2. Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries. Nam DH, Rodriguez C, Remacle AG, Strongin AY, Ge X. Proc Natl Acad Sci U S A 113 14970-14975 (2016)
  3. Imaging a functional tumorigenic biomarker in the transformed epithelium. LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS. Proc Natl Acad Sci U S A 110 93-98 (2013)
  4. A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior. Kromann-Hansen T, Oldenburg E, Yung KW, Ghassabeh GH, Muyldermans S, Declerck PJ, Huang M, Andreasen PA, Ngo JC. J Biol Chem 291 15156-15168 (2016)
  5. Accurate Structure Prediction of CDR H3 Loops Enabled by a Novel Structure-Based C-Terminal Constraint. Weitzner BD, Gray JJ. J Immunol 198 505-515 (2017)
  6. Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain. Fenn S, Schiller CB, Griese JJ, Duerr H, Imhof-Jung S, Gassner C, Moelleken J, Regula JT, Schaefer W, Thomas M, Klein C, Hopfner KP, Kettenberger H. PLoS One 8 e61953 (2013)
  7. A Machine Learning Approach for Hot-Spot Detection at Protein-Protein Interfaces. Melo R, Fieldhouse R, Melo A, Correia JD, Cordeiro MN, Gümüş ZH, Costa J, Bonvin AM, Moreira IS. Int J Mol Sci 17 E1215 (2016)
  8. Identification of highly selective MMP-14 inhibitory Fabs by deep sequencing. Lopez T, Nam DH, Kaihara E, Mustafa Z, Ge X. Biotechnol Bioeng 114 1140-1150 (2017)
  9. α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer. Han Z, Harris PK, Karmakar P, Kim T, Owusu BY, Wildman SA, Klampfer L, Janetka JW. ChemMedChem 11 585-599 (2016)
  10. Compact and modular multicolour fluorescence detector for droplet microfluidics. Cole RH, de Lange N, Gartner ZJ, Abate AR. Lab Chip 15 2754-2758 (2015)
  11. Monitoring protease activity in biological tissues using antibody prodrugs as sensing probes. Vasiljeva O, Menendez E, Nguyen M, Craik CS, Michael Kavanaugh W. Sci Rep 10 5894 (2020)
  12. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets. Franco FM, Jones DE, Harris PK, Han Z, Wildman SA, Jarvis CM, Janetka JW. Bioorg Med Chem 23 2328-2343 (2015)
  13. Functional selection of protease inhibitory antibodies. Lopez T, Mustafa Z, Chen C, Lee KB, Ramirez A, Benitez C, Luo X, Ji RR, Ge X. Proc Natl Acad Sci U S A 116 16314-16319 (2019)
  14. Matriptase Induction of Metalloproteinase-Dependent Aggrecanolysis In Vitro and In Vivo: Promotion of Osteoarthritic Cartilage Damage by Multiple Mechanisms. Wilkinson DJ, Wang H, Habgood A, Lamb HK, Thompson P, Hawkins AR, Désilets A, Leduc R, Steinmetzer T, Hammami M, Lee MS, Craik CS, Watson S, Lin H, Milner JM, Rowan AD. Arthritis Rheumatol 69 1601-1611 (2017)
  15. Development of a periplasmic FRET screening method for protease inhibitory antibodies. Nam DH, Ge X. Biotechnol Bioeng 110 2856-2864 (2013)
  16. Efficient Antibody Assembly in E. coli Periplasm by Disulfide Bond Folding Factor Co-expression and Culture Optimization. Rodriguez C, Nam DH, Kruchowy E, Ge X. Appl Biochem Biotechnol 183 520-529 (2017)
  17. Blocking the proteolytic activity of zymogen matriptase with antibody-based inhibitors. Tamberg T, Hong Z, De Schepper D, Skovbjerg S, Dupont DM, Vitved L, Schar CR, Skjoedt K, Vogel LK, Jensen JK. J Biol Chem 294 314-326 (2019)
  18. Inhibitory antibodies identify unique sites of therapeutic vulnerability in rhinovirus and other enteroviruses. Meng B, Lan K, Xie J, Lerner RA, Wilson IA, Yang B. Proc Natl Acad Sci U S A 117 13499-13508 (2020)
  19. An unexpected switch in peptide binding mode: from simulation to substrate specificity. Kahler U, Fuchs JE, Goettig P, Liedl KR. J Biomol Struct Dyn 36 4072-4084 (2018)
  20. Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein. Mitchell AC, Kannan D, Hunter SA, Parra Sperberg RA, Chang CH, Cochran JR. J Biol Chem 293 4969-4980 (2018)
  21. Novel Inhibitors and Activity-Based Probes Targeting Trypsin-Like Serine Proteases. Ferguson TEG, Reihill JA, Martin SL, Walker B. Front Chem 10 782608 (2022)
  22. Protease Inhibition Mechanism of Camelid-like Synthetic Human Antibodies. Nam DH, Lee KB, Kruchowy E, Pham H, Ge X. Biochemistry 59 3802-3812 (2020)
  23. Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable Antibodies. Howng B, Winter MB, LePage C, Popova I, Krimm M, Vasiljeva O. Pharmaceutics 13 1390 (2021)
  24. Substrate derived sequences act as subsite-blocking motifs in protease inhibitory antibodies. Choe H, Antee T, Ge X. Protein Sci 32 e4691 (2023)
  25. Antibodies raised against a Sunn bug (Eurygaster integriceps Put.) recombinant protease, rGHP3p2, can inhibit gluten-hydrolyzing activity. Dolgikh V, Tsarev A, Timofeev S, Zhuravlyov V, Senderskiy I, Lovegrove A, Konarev A. Food Sci Nutr 8 703-708 (2020)
  26. Generation of highly selective monoclonal antibodies inhibiting a recalcitrant protease using decoy designs. Lee KB, Dunn ZS, Lopez T, Mustafa Z, Ge X. Biotechnol Bioeng 117 3664-3676 (2020)
  27. Identification of recombinant Fabs for structural and functional characterization of HIV-host factor complexes. Sevillano N, Green EM, Votteler J, Kim DY, Ren X, Yang B, Liu X, Lourenço AL, Hurley JH, Farr-Jones S, Gross JD, Cheng Y, Craik CS. PLoS One 16 e0250318 (2021)
  28. Matriptase drives dissemination of ovarian cancer spheroids by a PAR-2/PI3K/Akt/MMP9 signaling axis. Pawar NR, Buzza MS, Duru N, Strong AA, Antalis TM. J Cell Biol 222 e202209114 (2023)